Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.

Bertoli S, Tavitian S, Picard M, Huguet F, Vergez F, Delabesse E, Sarry A, Bérard E, Récher C.

Leuk Res. 2018 Dec;75:7-10. doi: 10.1016/j.leukres.2018.10.015. Epub 2018 Oct 31. No abstract available.

PMID:
30419550
2.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher MV, Vergez F, Delabesse E, Sarry A, Huguet F, Larrue C, Bosc C, Farge T, Sarry JE, Michallet M, Récher C.

Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.

PMID:
30325535
3.

[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].

Gauthier M, Comont T, Vergez F, Ysebaert L.

Bull Cancer. 2018 Nov;105(11):1042-1051. doi: 10.1016/j.bulcan.2018.07.008. Epub 2018 Sep 20. Review. French.

PMID:
30243477
4.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

5.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers.

Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, Caron N, Voisin M, Cherier J, Ligat L, Lopez F, Noguer E, Rives A, Payré B, Saati TA, Lamaziere A, Despres G, Lobaccaro JM, Baron S, Demur C, de Toni F, Larrue C, Boutzen H, Thomas F, Sarry JE, Tosolini M, Picard D, Record M, Récher C, Poirot M, Silvente-Poirot S.

Nat Commun. 2017 Dec 4;8(1):1903. doi: 10.1038/s41467-017-01948-9.

6.

Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells.

Bhavanasi D, Wen KW, Liu X, Vergez F, Danet-Desnoyers G, Carroll M, Huang J, Klein PS.

Blood Cancer J. 2017 Nov 30;7(12):636. doi: 10.1038/s41408-017-0003-1. No abstract available.

7.

Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.

Ribes D, Hachem HEL, Oberic L, Vergez F, Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, Laurent C, Huart A, Chauveau D, Ysebaert L, Faguer S.

Am J Hematol. 2018 Mar;93(3):356-362. doi: 10.1002/ajh.24984. Epub 2017 Dec 6.

8.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

9.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

10.

Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Tosolini M, Pont F, Poupot M, Vergez F, Nicolau-Travers ML, Vermijlen D, Sarry JE, Dieli F, Fournié JJ.

Oncoimmunology. 2017 Feb 6;6(3):e1284723. doi: 10.1080/2162402X.2017.1284723. eCollection 2017.

11.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
12.

Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis.

Ribes D, Casemayou A, El Hachem H, Laurent C, Guilbeau-Frugier C, Vergez F, Tavitian S, Schanstra JP, Chauveau D, Bascands JL, Ysebaert L, Faguer S.

Clin Exp Nephrol. 2017 Oct;21(5):781-786. doi: 10.1007/s10157-016-1373-6. Epub 2016 Dec 26.

PMID:
28018996
13.

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.

Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, Farge T, Vergez F, Récher C, Sarry JE, Kim KW, Shin HY, Dicato M, Diederich M.

Leukemia. 2017 Mar;31(3):755-759. doi: 10.1038/leu.2016.341. Epub 2016 Nov 22. No abstract available.

14.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C.

Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262.

15.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

16.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

17.

Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.

Tavitian S, Denis A, Vergez F, Berard E, Sarry A, Huynh A, Delabesse E, Luquet I, Huguet F, Récher C, Bertoli S.

Am J Hematol. 2016 Feb;91(2):193-8. doi: 10.1002/ajh.24228. Epub 2015 Nov 26.

18.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.

Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S, Sarry JE, Récher C.

Blood. 2016 Feb 18;127(7):882-92. doi: 10.1182/blood-2015-05-646497. Epub 2015 Aug 18.

19.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

20.

Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.

Lebon D, Vergez F, Bertoli S, Harrivel V, De Botton S, Micol JB, Marolleau JP, Récher C.

Leuk Res. 2015 Aug;39(8):818-21. doi: 10.1016/j.leukres.2015.05.001. Epub 2015 May 14.

PMID:
26002512
21.

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE.

Blood Cancer J. 2015 Mar 20;5:e297. doi: 10.1038/bcj.2015.19.

22.

Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis.

Faguer S, Vergez F, Peres M, Ferrandiz I, Casemayou A, Belliere J, Cointault O, Lavayssiere L, Nogier MB, Prevot G, Huart A, Recher C, Rostaing L.

Hematol Oncol. 2016 Mar;34(1):55-7. doi: 10.1002/hon.2174. Epub 2014 Oct 13. No abstract available.

PMID:
25312407
23.

Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas.

Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C, Huart A, Tavitian S, El Hachem H, Oberic L, Chauveau D, Michallet AS, Ysebaert L, Faguer S.

Am J Hematol. 2014 Oct;89(10):969-73. doi: 10.1002/ajh.23798. Epub 2014 Jul 30.

24.

The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.

Bossis G, Sarry JE, Kifagi C, Ristic M, Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, Pelegrin M, Kaoma T, Vallar L, Récher C, Manenti S, Piechaczyk M.

Cell Rep. 2014 Jun 26;7(6):1815-23. doi: 10.1016/j.celrep.2014.05.016. Epub 2014 Jun 5.

25.

Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia.

Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguet F, Michallet M, Dumontet C, Recher C, Thomas X.

Leuk Lymphoma. 2014 Apr;55(4):855-62. doi: 10.3109/10428194.2013.813504. Epub 2013 Aug 5.

PMID:
23786457
26.

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA.

Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.

27.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C.

Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30.

28.

Class I phosphoinositide 3-kinases in normal and pathologic hematopoietic cells.

Vergez F, Recher C, Payrastre B.

Curr Top Microbiol Immunol. 2012;362:163-84. doi: 10.1007/978-94-007-5025-8_8. Review.

PMID:
23086418
29.

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.

Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C.

Leukemia. 2013 Feb;27(2):325-35. doi: 10.1038/leu.2012.240. Epub 2012 Aug 20.

PMID:
22902361
30.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, Dastugue N, Strzelecki AC, Cavelier C, Creancier L, Pillon A, Kruczynski A, Demur C, Sarry A, Huguet F, Huynh A, Récher C, Delabesse E.

Oncotarget. 2011 Nov;2(11):850-61.

31.

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V.

Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.

32.

Canine reference intervals for coagulation markers using the STA Satellite(R) and the STA-R Evolution(R) analyzers.

Geffré A, Grollier S, Hanot C, Vergez F, Trumel C, Braun JP.

J Vet Diagn Invest. 2010 Sep;22(5):690-5.

PMID:
20807922
33.

A multicentric retrospective study of serum/plasma urea and creatinine concentrations in dogs using univariate and multivariate decision rules to evaluate diagnostic efficiency.

Concordet D, Vergez F, Trumel C, Diquélou A, Lanore D, Le Garrérès A, Pagès JP, Péchereau D, Médaille C, Braun JP.

Vet Clin Pathol. 2008 Mar;37(1):96-103. doi: 10.1111/j.1939-165X.2008.00007.x.

PMID:
18366551
34.

Comparison of plasma/serum urea and creatinine concentrations in the dog: a 5-year retrospective study in a commercial veterinary clinical pathology laboratory.

Médaille C, Trumel C, Concordet D, Vergez F, Braun JP.

J Vet Med A Physiol Pathol Clin Med. 2004 Apr;51(3):119-23.

PMID:
15214851

Supplemental Content

Loading ...
Support Center